SCHEMBL1090664

SCHEMBL1090664

c1ccc(COc2cccc(CN3CC(Nc4nccc(N5CCCCCC5)n4)C3)c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 2/20 0.67
HTT P42858 3/20 0.53
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.53
LMNA P02545 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
HPGD P15428 1/20 0.53
TSHR P16473 1/20 0.53
ALOX12 P18054 1/20 0.53
FAAH O00519 3/20 0.48
GRIN1 Q05586 1/20 0.43
GRIN2B Q13224 1/20 0.43
HRH3 Q9Y5N1 1/20 0.42
CASP1 P29466 1/20 0.41
CASP4 P49662 1/20 0.41
CASP5 P51878 1/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
HRH4 Q9H3N8 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1088933 0.94 CXCR4 (0.78) CXCR4HTTKDM4EALDH1A1LMNA
SCHEMBL1089428 0.93 CXCR4 (0.70) CXCR4HTTKDM4EALDH1A1LMNA
SCHEMBL1090100 0.92 CXCR4 (0.68) CXCR4HTTKDM4EALDH1A1LMNA
SCHEMBL1091212 0.92 CXCR4 (0.68) CXCR4HTTKDM4EALDH1A1LMNA
SCHEMBL1091839 0.91 CXCR4 (0.72) CXCR4HTTKDM4EALDH1A1SMN1; SMN2
SCHEMBL1091510 0.89 CXCR4 (0.63) CXCR4KDM4EALDH1A1FAAHHRH3
SCHEMBL1089797 0.88 CXCR4 (0.66) CXCR4HTTKDM4EALDH1A1LMNA
SCHEMBL1089573 0.87 CXCR4 (0.85) CXCR4HRH3HRH4ACHEBACE1
SCHEMBL1089509 0.85 CXCR4 (0.67) CXCR4HRH3HRH4ACHEBACE1
SCHEMBL1088883 0.85 CXCR4 (0.79) CXCR4HTTKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 US disclosed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885HTT 3256/4885KDM4E 2001/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 CXCR4 1/4885HTT 3256/4885KDM4E 2001/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885HTT 3256/4885KDM4E 2001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.